Shares of Wockhardt are locked at upper circuit after the pharma company said on September 19 that one of its investigational ...

EQS-News: BRAIN Biotech AG / Key word (s): Contract BRAIN Biotech AG concludes major pharma compound transaction valued up to EUR 128.88 million from its BioIncubator 20.09.2024 / 19:50 CET/CEST ...

ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord ...

Truist Securities initiated coverage on Protagonist Therapeutics Inc (NASDAQ:PTGX), citing its first-in-class lead asset with ...

Moderna Inc. (NASDAQ:MRNA) is developing mRNA-1769 as a mpox vaccine for use in adults. Currently, a Phase 1/2 trial ...

OmRx Oncology, or “OmRx,” a new biopharmaceutical venture with investment from Scripps Research, launched with a Phase 2 clinical asset in-licensed fr ...

Wockhardt's investigational drug, Zaynich (Zidebactam/Cefepime), has successfully treated over 35 critically ill patients in India and US who were suffering from extremely drug-resistant infections ...

AstraZeneca Plc (NASDAQ:AZN) shared detailed results from the TROPION-Lung01 Phase 3 of datopotamab deruxtecan (Dato-DXd) ...

The most frequently used mpox vaccine provides partial immunity to the disease but isn't always able to prevent severe symptoms or disease transmission. A new vaccine candidate from Moderna, mRNA-1769 ...

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Company's IPAX-1 Phase I study has been ...

Following an investigational new drug application clearance from the FDA, a phase 1 trial plans to evaluate CD-001.